ternational clinical trial programs in COPD comprising 10 studies in total with more than 7,000 patients across 42 countries[1-5,13-20]
. The first five studies (ILLUMINATE, SHINE, BRIGHT, ENLIGHTEN, SPARK) have already completed in 2012 with three additional studies (BLAZE, ARISE, BEACON) expected to complete by the end of the year. The studies are designed to investigate efficacy, safety and tolerability, exercise endurance, exacerbations, breathlessness and quality of life[1-5,13-17]
CEO of Sosei, Shinichi Tamura commented:
"The SPARK study demonstrated a meaningful reduction in exacerbations in COPD patients; something that is of major benefit for patients and doctors and eases the burden of healthcare costs. We look forward to more detailed data from both glycopyrronium bromide (NVA237) and QVA149 at the upcoming European Respiratory Society meeting in Vienna in early September with the first filings for QVA149 expected in Europe and Japan by the end of this year."
Notes for editors
NVA237 (glycopyrronium bromide - Seebri® Breezhaler®) was licensed to Novartis in April 2005 by Sosei and its co-development partner, Vectura. It is an investigational LAMA developed as a once-daily inhaled maintenance therapy for the treatment of COPD. Phase III data from the GLOW1, 2 and 3 studies demonstrated that glycopyrronium bromide increased patients' lung function over a 24-hour period compared to placebo with a fast onset of action at first dose, and improved exercise endurance versus placebo[21-23].
QVA149 is an investigational inhaled, once-daily, fixed-dose combination of NVA237 and the LABA, indacaterol maleate, for which Novartis received European regulatory approval as Onbrez® B
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1
|SOURCE Sosei Group Corporation|
Copyright©2012 PR Newswire.
All rights reserved
. Sosei Announces Successful Completion of Phase I Study for SO-1105 for the Treatment of Oropharyngeal Candidiasis2
. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug3
. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference4
. BioNeutral Group Receives $400,000 in Equity Financing5
. MiMedx Group Completes $5,000,000 Private Placement6
. Use Biomarkers in Alzheimers Disease Clinical Trials, Says Expert Group7
. MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD8
. Lend Lease Announces the Appointment of Tom Chapman as Director Operations for the Life Sciences Group in the Atlantic Region9
. Statewide Network of Angel Investor Groups Announced in Alabama10
. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2011 Financial Results on Wednesday, March 7, 201211
. Weikang Bio-Technology Group Co., Inc. Is Expected to Achieve the Net Profit of at Least $26 Million